ДАБИГАТРАН И ИДАРУЦИЗУМАБ. НОВЫЕ ВОЗМОЖНОСТИ ОБЕСПЕЧЕНИЯ БЕЗОПАСНОСТИ ПАЦИЕНТОВ

The widespread use of new oral anticoagulants in clinical practice requires improving the safety of medication use, i.e. the use of specific reversal agents, if necessary. Idarucizumab, a humanied monoclonal antibody fragment, is the first reversal agent authorized in our country that binds to dabigatran. Its efficacy and safety have been validated in several clinical trials, and its use gains experience in real clinical practice.

• Publication year

  2019

• Venue

  Unknown venue

• Publication date

  2019-06-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.21518/2307-1109-2019-1-53-61
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding

  2019cited by this paper
• Idarucizumab dosing in patients with excessive dabigatran body burden.

  2019cited by this paper
• 59: ANDEXANET ALFA REVERSES ANTICOAGULATION IN FACTOR XA-ASSOCIATED MAJOR BLEEDING IN ANNEXA-4 STUDY

  2019cited by this paper
• Thrombolysis in Acute Ischemic Stroke after Idarucizumab for Dabigatran Etexilate Reversal in Elderly: A Case Report.

  2018cited by this paper
• Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation

  2018cited by this paper
• Reversal agents for non-vitamin K antagonist oral anticoagulants

  2018cited by this paper
• Performance of idarucizumab as antidote of dabigatran in daily clinical practice

  2018cited by this paper
• Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

  2017cited by this paper
• Bleeding related to non-vitamin K antagonist oral anticoagulants in emergency department: A "Real-world" snapshot from Southern Italy. On behalf of MIRC-NOAC study group.

  2017cited by this paper
• 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

  2017cited by this paper
• Intravenous thrombolysis for stroke after Dabigatran reversal with Idarucizumab: an update

  2017cited by this paper
• Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence

  2017cited by this paper
• Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

  2017cited by this paper
• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

  2016cited by this paper
• Management of Dabigatran‐Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis

  2016cited by this paper
• Adherence to oral anticoagulant therapy in patients with atrial fibrillation

  2016cited by this paper
• The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes

  2016cited by this paper
• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

  2016cited by this paper
• Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

  2015cited by this paper
• Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology

  2015cited by this paper
• Idarucizumab for Dabigatran Reversal.

  2015cited by this paper
• Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

  2015cited by this paper
• The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

  2013cited by this paper
• A specific antidote for dabigatran: functional and structural characterization.

  2013cited by this paper
• Patient outcomes using the European label for dabigatran

  2013cited by this paper
• Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

  2012cited by this paper
• Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

  2011cited by this paper
• Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper

• No citing papers are available for this paper.